Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.
Henick BS, Koch PD, Gainor JF, Awad MM, Chiuzan C, Izard S, Georgis Y, Mallick S, Garofano RF, Wong CV, Saqi A, Grindheim J, Schulze K, Sonett JR, Rizvi NA, Izar B, Taylor AM, Shu CA.
Henick BS, et al. Among authors: shu ca.
J Immunother Cancer. 2024 Dec 25;12(12):e009301. doi: 10.1136/jitc-2024-009301.
J Immunother Cancer. 2024.
PMID: 39721753
Free article.
Clinical Trial.